Gabriel Kabarriti, Ali Elsayed, Giannis A Moustafa, Nickisa Hodgson
{"title":"Orbital inflammatory disease in a primarily black patient population.","authors":"Gabriel Kabarriti, Ali Elsayed, Giannis A Moustafa, Nickisa Hodgson","doi":"10.3389/fopht.2025.1576929","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study is to characterize orbital inflammatory disease (OID) in a primarily Black patient population, examining their demographics, presentations, workup, treatment, and outcome.</p><p><strong>Methods: </strong>A retrospective study was performed from January 2005 to June 2022 at two academic institutions in Brooklyn, NY. Patients included met criteria for one of the following OID conditions: non-specific orbital inflammation; nonbacterial dacryoadenitis; Tolosa-Hunt; orbital myositis; definite, possible, or probable IgG4-related ophthalmic disease; and sclerosing orbital inflammation. Data reviewed included orbital inflammatory labs, imaging, pathology, and treatment. Treatment was considered successful if a patient had complete resolution of symptoms.</p><p><strong>Results: </strong>Thirty-nine patients met criteria for this study. 35.9% were diagnosed with dacryoadenitis, 28.2% with NSOI, 12.8% with myositis, 5.1% with possible IgG-ROD, 7.7% with probable IgG4-ROD, 7.7% with Tolosa Hunt, and 2.6% with sclerosing OI. 91% were started on steroids; 12.8% required transition to steroid-sparing therapy. 85% had a successful outcome with a resolution of symptoms.</p><p><strong>Conclusions: </strong>This study characterizes OID in a Black patient population and compares it to prior studies done on OID. Research on underrepresented patient populations is needed to understand differences in disease presentation and improve patient outcomes.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"5 ","pages":"1576929"},"PeriodicalIF":0.9000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137059/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fopht.2025.1576929","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The purpose of this study is to characterize orbital inflammatory disease (OID) in a primarily Black patient population, examining their demographics, presentations, workup, treatment, and outcome.
Methods: A retrospective study was performed from January 2005 to June 2022 at two academic institutions in Brooklyn, NY. Patients included met criteria for one of the following OID conditions: non-specific orbital inflammation; nonbacterial dacryoadenitis; Tolosa-Hunt; orbital myositis; definite, possible, or probable IgG4-related ophthalmic disease; and sclerosing orbital inflammation. Data reviewed included orbital inflammatory labs, imaging, pathology, and treatment. Treatment was considered successful if a patient had complete resolution of symptoms.
Results: Thirty-nine patients met criteria for this study. 35.9% were diagnosed with dacryoadenitis, 28.2% with NSOI, 12.8% with myositis, 5.1% with possible IgG-ROD, 7.7% with probable IgG4-ROD, 7.7% with Tolosa Hunt, and 2.6% with sclerosing OI. 91% were started on steroids; 12.8% required transition to steroid-sparing therapy. 85% had a successful outcome with a resolution of symptoms.
Conclusions: This study characterizes OID in a Black patient population and compares it to prior studies done on OID. Research on underrepresented patient populations is needed to understand differences in disease presentation and improve patient outcomes.